If you haven't done rare disease, sorry but then you don't know rare disease. We KNOW Rare Disease, we have done what you are doing and we know how hard it is, and we know how limited the solutions are in finding rare disease patients. It was out of that frustration that this solution was born.
We target COMMUNITY based health care systems. It is in the community systems where as much as 80% of patients reside, and it is where the diagnostic odyssey is most pronounced. Our focus is to partner with these providers to raise the bar in rare disease diagnosis & care
We are analyzing real & active Electronic Health Record data, driving the discovery & diagnosis of real patients. We use machine learning and AI to find high probable patients in need of a further evaluation and diagnostic confirmation.
We aren't guessing where patients might be, we help providers find real live rare disease patients lost in the system in a diagnostic odyssey. Patients with probable disease, and we help you find those providers, so you can serve the patient
Because of our partnership and revenue sharing with healthcare Providers & Systems, we can drive the pull through of "probable" patients to a conclusive diagnosis. This creates a sense of urgency and motivation necessary to change the status quo
The US healthcare system is a volume based business built for the masses and Rare Disease Patients. are outside the bandwidth of most providers, which explains the 5-8 year diagnostic odyssey of most rare disease patients. No one in health care is proactively looking for these special patients and you can't find what you aren't looking for
Overwhelmed and Under Supported Providers with Rare Disease Patients they are not equipped to consistently manage or find a one in a million patient. There are now 5300 medical journals producing 800,000 articles a year, no one can keep up with that
This was true before RDDT, but we are changing the marketplace. Like it or not we have a capitalistic health care system and they prioritize strategies around revenue. By making the discovery and diagnosis of these patients valuable, we can transform the Rare Disease marketplace
Why would anyone look for a subset of patients they don't believe they have and they really don't want to find? Particularly when they have no ROI potential.
80% of patient volume now resides within the consolidated, community based, vertically integrated health care systems, and we can offer a portal to mine their data to drive the diagnosis of targeted rare diseases
It is getting more and more difficult for industry to get quality time with important providers and patients are paying the price, and this problem is compounded, when it comes to complex and nuanced rare disease patients
Because of superior EHR data and rare disease expertise, we can efficiently and rapidly discover likely rare disease patients, drive them to diagnosis and tell you which providers have them
RDDT is a middle man that empowers healthcare and biotech to compliantly work for the benefit of the patient. With Biotech funding the analytics, RDDT executing the analysis and Healthcare providing the data and being rewarded through revenue share from RDDT, powerful new tools can be deployed to accelerate the discovery of these hard to find patients.
Industry Funds the data searches for rare disease patients that are lost in a healthcare system, and in doing so accelerates the discovery, identification and diagnosis of those patients
By creating a compliant platform for biotech & healthcare to collaborate and coordinate the acceleration of diagnosis, we can transform the marketplace in a way that is good for everyone
We make short list of patients for providers and short list of providers for Biotech. It may not be exactly "easy", but it is light years better than the status quo
No Patient Data, Just Providers with Probable Rare Disease Patients that can be easily identified by the Provider for follow up. So when you say, "I hear you have a patient", the Provider doesn't answer, "Really? Who?" He will know
We are simultaneously providing "probable" patient list to providers in need of further evaluation. Interrupting the diagnostic odyssey of rare disease patients and putting them on a pathway to either treatment or trial
With everyone having a short list, now industry knows which providers to give the free diagnostic testing to and providers know who to diagnostically test, for the benefit of the patient
Claims data is retrospective, instead of prospective and has limited insightful data points and produces nothing more than bad guesses
Because of our relationship with health care we can actively facilitate the diagnostic pull through of patients to a point of conclusion. We deal in conclusive diagnosis of rare disease patients not hypothetical guesses
RDDT's process removes thy mystery for providers, we help them find patients and then we help bio-pharma find the right providers
Once we find lost rare disease patients, we buy from our provider partners de-identified data on those rare disease patients to advance the study and of that disease and accelerate research and development
Nashville, Tennessee, United States